Back to search results

Cardiac Amyloidosis and Physical Activity (CAPACITY) Study

This study, called CAPACITY, is looking at how a supervised exercise program called Cardiac Rehabilitation can help people with cardiac amyloidosis (a condition where abnormal proteins build up in the heart). You might be able to join if you are over 18, have heart failure (NYHA Class I-III), can exercise, are on stable treatment for cardiac amyloidosis, and are expected to live at least 6 months. The main goal is to see how many participants complete at least 75% of the planned 36 Cardiac Rehabilitation sessions over 12 weeks. The study is currently recruiting participants.

Study design
This is an interventional study with a planned enrollment of 50 participants. The study is not specified as randomized or blinded.
What's involved
If you join, you will have a baseline 6-minute walk test and cardiopulmonary exercise test (CPET). Then, you will participate in a supervised cardiac rehabilitation program with 3 one-hour sessions per week for 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 12, which suggests follow-up for at least 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06096675

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Recruiting
NAAges 18+InterventionalSupportive care
Wake Forest University Health Sciences
~50 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:• Cardiac Rehabilitation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants that complete at least 75% of prescribed cardiac rehab sessions
Measured over Week 12

Conditions

Cardiac Amyloidosis

Explore related trials

Cardiac AmyloidosisHeart Failure

NCT06096675

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Sanger Heart and Vascular Institute

    Charlotte, North Carolinastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jai Singh, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Dana B Amaro, RN
[email protected]
704-355-4692
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \> 18
New York Heart Association (NYHA) Class I-III Heart Failure
Able to Exercise
On stable treatment for their cardiac amyloidosis or under active surveillance
Life expectancy of at least 6 months
Ability to understand and the willingness to sign a written informed consent document in English, and the willingness/ability to comply with the protocol activities
Participant must be able and willing to follow the cardiac rehabilitation activities

Exclusion

Inability to provide informed consent
Inability to commit to in-person supervised exercise sessions for three one-hour sessions a week for 12 weeks
NYHA Class IV Heart Failure
Pulmonary disease requiring home oxygen
Gait instability or history of prior falls
In the opinion of the Principal Investigator, have a clinically significant comorbid disease that is likely to affect the ability of the patient to complete the trial, interfere with their ability with measurement of self-reported outcomes.

What this trial measures

  • Number of participants that complete at least 75% of prescribed cardiac rehab sessionsWeek 12

    Feasibility of cardiac rehab as measured by number of participants that complete at least 75% of prescribed cardiac rehab sessions.